文献速递肝病

老年晚期肝病患者接受无干扰素治疗的研究

Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.
PubMed 文献 · Am J Gastroenterol · 2017-06-06

该研究回顾性分析了西班牙国家登记处中1252例65岁及以上接受无干扰素方案治疗的丙型肝炎病毒(HCV)患者,总体持续病毒学应答(SVR12)率为94%,且三个年龄组间无差异;白蛋白≤3.5 g/dl是唯一独立负性预测因素;严重不良事件和死亡率随年龄增长而升高。

要点

  • 老年HCV患者接受无干扰素方案的SVR12率为94%,三个年龄组间无差异。
  • 白蛋白≤3.5 g/dl是治疗失败的唯一独立负性预测因素。
  • 严重不良事件率和死亡率随年龄增长而升高,年龄≥75岁和白蛋白≤3.5 g/dl是死亡的主要预测因素。

核心结论

  • 无干扰素方案在老年患者中SVR率高,与一般人群相当;基线低白蛋白水平(≤3.5 g/dl)是治疗失败的唯一预测因素;严重不良事件和死亡率随年龄增长而升高;年龄≥75岁或晚期肝病(白蛋白≤3.5 g/dl)患者死亡率更高;因此推荐仔细选择患者进行抗病毒治疗。

研究设计与样本

  • 回顾性分析西班牙国家登记处(Hepa-C)中年龄≥65岁接受无干扰素方案的HCV患者,共记录1252例患者数据。

主要发现

  • 955例(76%)年龄65-74岁,211例(17%)年龄75-79岁,86例(7%)年龄≥80岁;HCV基因1b型占88%,48%为既往无应答者;922例(74%)有肝硬化,其中11%表现为失代偿期肝病;最常用方案为SOF/LDV(33%)、3D(28%)和SOF/SMV(26%),49%加用利巴韦林;总体SVR12率为94%,三个年龄组间无差异;白蛋白≤3.5 g/dl是唯一独立负性预测因素(0.25(0.15-0.41);P<0.01);严重不良事件率随年龄组增加(8.8%、13%和14%;P=0.04);死亡率2.3%,主要预测因素为年龄≥75岁(2.59(1.16-5.83);P=0.02)和白蛋白≤3.5 g/dl(17(6.3-47);P<0.01)。

临床怎么用

  • 作者推荐对老年患者进行抗病毒治疗时仔细选择患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Interferon-free therapies have an improved safety and efficacy profile. However, data in elderly patients, who have frequently advanced liver disease, associated comorbidities, and use concomitant medications are scarce. The im of this study was to assess the effectiveness and tolerability of all-oral regimens in elderly patients in real-life clinical practice. METHODS: Retrospective analysis of hepatitis C virus (HCV) patients aged ≥65 years receiving interferon-free regimens within the Spanish National Registry (Hepa-C). RESULTS: Data of 1,252 patients were recorded. Of these, 955 (76%) were aged 65-74 years, 211 (17%) were aged 75-79 years, and 86 (7%) were aged ≥80 years at the start of antiviral therapy. HCV genotype-1b was predominant (88%) and 48% were previous non-responders. A significant proportion of patients had cirrhosis (922; 74%), of whom 11% presented decompensated liver disease. The most used regimens were SOF/LDV (33%), 3D (28%), and SOF/SMV (26%). Ribavirin was added in 49% of patients. Overall, the sustained virological response (SVR12) rate was 94% without differences among the three age categories. Albumin ≤3.5 g/dl was the only independent negative predictor of response (0.25 (0.15-0.41); P<0.01). Regarding tolerability, the rate of severe adverse events increased with age category (8.8, 13, and 14%; P=0.04). In addition, the main predictors of mortality (2.3%) were age ≥75 years (2.59 (1.16-5.83); P =0.02) and albumin ≤3.5 (17 (6.3-47); P <0.01). CONCLUSIONS: SVR rates with interferon-free regimens in elderly patients are high and comparable to the general population. Baseline low albumin levels (≤3.5 g/dl) was the only predictor of treatment failure. Importantly, the rate of severe adverse events and death increased with age. Elderly patients (≥75 years) or those with advanced liver disease (albumin ≤3.5) presented higher mortality. Thus a careful selection of patients for antiviral treatment is recommended.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Lens S, Fernández I, Rodríguez-Tajes S, et al. Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. Am J Gastroenterol. 2017. PMID: 28585554. doi:10.1038/ajg.2017.157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。